MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review

June 2020 | 50 pages | ID: M1682B739FBEN
GlobalData

Abstracts

MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for the treatment of serious and rare cardiovascular diseases including heritable cardiomyopathies. Its lead drug product candidate, mavacamten, is intended for the treatment of hypertrophic cardiomyopathy (HCM). Its other pipeline product candidates include danicamtiv (formerly MYK-491) is being developed for treating genetic dilated cardiomyopathy (DCM) and systolic heart failure; MYK-224, a small molecule for treating HCM; ACT-1 for systolic heart failure, and LUS-1, for treating diastolic heart failure. The company collaborates with healthcare organizations for the development and commercialization of its pipeline products. MyoKardia is headquartered in Brisbane, California, the US.

MyoKardia Inc Key Recent Developments

May 06,2020: MyoKardia reports first quarter 2020 financial results
Feb 27,2020: MyoKardia reports fourth quarter and full year 2019 financial results
Nov 04,2019: MyoKardia reports third quarter 2019 financial results
Aug 15,2019: MyoKardia launches 2nd Annual MyoSeeds research grants program to advance independent research in heart disease
Aug 15,2019: MyoKardia Launches 2nd Annual MyoSeeds Research Grants Program to Advance Independent Research in Heart Disease

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

MyoKardia Inc - Key Facts
MyoKardia Inc - Key Employees
MyoKardia Inc - Key Employee Biographies
MyoKardia Inc - Major Products and Services
MyoKardia Inc - History
MyoKardia Inc - Company Statement
MyoKardia Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
MyoKardia Inc - Business Description
MyoKardia Inc - Corporate Strategy
MyoKardia Inc - SWOT Analysis
SWOT Analysis - Overview
MyoKardia Inc - Strengths
MyoKardia Inc - Weaknesses
MyoKardia Inc - Opportunities
MyoKardia Inc - Threats
MyoKardia Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
MyoKardia Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 06, 2020: MyoKardia reports first quarter 2020 financial results
Feb 27, 2020: MyoKardia reports fourth quarter and full year 2019 financial results
Nov 04, 2019: MyoKardia reports third quarter 2019 financial results
Aug 15, 2019: MyoKardia launches 2nd Annual MyoSeeds research grants program to advance independent research in heart disease
Aug 15, 2019: MyoKardia Launches 2nd Annual MyoSeeds Research Grants Program to Advance Independent Research in Heart Disease
May 09, 2019: MyoKardia reports first quarter 2019 financial results
May 07, 2019: MyoKardia announces inaugural MyoSeeds Research Grants Program awardees
Feb 28, 2019: MyoKardia reports fourth quarter and full year 2018 financial results
Jan 23, 2019: MyoKardia names William Fairey as Chief Commercial Officer
Jan 03, 2019: Sanofi offloads drug programmes to MyoKardia and Acer Therapeutics

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

MyoKardia Inc, Key Facts
MyoKardia Inc, Key Employees
MyoKardia Inc, Key Employee Biographies
MyoKardia Inc, Major Products and Services
MyoKardia Inc, History
MyoKardia Inc, Subsidiaries
MyoKardia Inc, Key Competitors
MyoKardia Inc, Ratios based on current share price
MyoKardia Inc, Annual Ratios
MyoKardia Inc, Annual Ratios (Cont...1)
MyoKardia Inc, Interim Ratios
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
MyoKardia Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

MyoKardia Inc, Performance Chart (2015 - 2019)
MyoKardia Inc, Ratio Charts
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Amgen Inc
Takeda Pharmaceuticals America Inc
Bristol-Myers Squibb Co
Zensun (Shanghai) Sci & Tech Co Ltd
Novartis Corp
Bayer AG